Pfizer has asked the Food and Drug Administration for emergency authorization for the use of the booster dose of the vaccine in the US for all over 18. The company has announced that the request is based on the results of the Trial – phase 3 which involved over 10,000 participants. The booster dose, as it was already announced in October, was found to be safe and proved to be 95% effective against symptomatic forms of covid. “No additional safety risks have been identified,” Pfizer said in relation to adverse events associated with the vaccine.
Pfizer has already obtained the authorization for the administration of the booster dose to the over 65s, to frail subjects and to those considered at high risk of infections. The Pfizer booster dose can also be given to those who have received other vaccines on their regular cycle.
#Pfizer #request #booster #dose #adults #USA